SRC and breast lobular carcinoma: Together with the observation of high c-Src levels in patients with relapses, our data suggest a clinical benefit of c-Src inhibition in LBC patients, advocating the evaluation of c-Src inhibitors as novel chemotherapeutic options in lobular carcinoma.